

4 November 2024

Osteopore to join forces with renowned scientists to drive innovations in Regenerative Medicine

Highlights

- Osteopore signs Investment Agreement with renowned, internationally recognised scientists who are pioneering leaders in regenerative medicine and aging science.
- The investment marks a key step in Osteopore's strategy to diversify into upstream cellular regeneration while strengthening its position in the regenerative medicine space.
- Osteopore proposes a strategic investment into the upcoming entity founded by Dr Xianmin Zeng and Dr Brian Kennedy, combining biotech and medtech to advance tissue regeneration, cure diseases and promotion of geroscience and longevity.
- The strategic investment enhances Osteopore's exposure to the USD 15.07b stem cell market, which is projected to grow to USD 56.15b at a CAGR of 16.1% by 2032¹.

Australian-Singaporean regenerative medicine company **Osteopore Limited** (ASX: **OSX**; **Osteopore** or **the Company**) – a global leader in 3D-printed biomimetic and bioresorbable implants – is pleased to announce that it has signed an Investment Agreement for strategic investment into a new entity ("Regen SPV") to be setup by prominent and internationally recognised scientists Dr Xianmin Zeng and Dr Brian Kennedy.

¹ <https://www.fortunebusinessinsights.com/stem-cells-market-105138>



Through the proposed strategic investment, Osteopore solidifies its commitment to advancing cutting-edge regenerative technologies that drive meaningful change while maintaining commercial viability.

As co-Founders of Regen SPV, Dr Zeng and Dr Kennedy will focus on integrating biotech and medtech to drive breakthroughs in tissue regeneration, disease cures, and the promotion of geroscience and longevity. Their work will continue to advance the broader understanding of aging and the application of regenerative medicine and cellular therapies to extend healthspan and combat age-related conditions.

Dr Xianmin Zeng is a leading expert in stem cell biology specialising in human embryonic stem cells and induced pluripotent stem cells (iPSC). Her research focuses on neural development using iPSC to model neurodegenerative diseases and bridges basic science and translational applications, making her a key figure in regenerative medicine and stem cell therapy.

Dr Zeng is the founder of USA-based RxCell Inc. – a leading iPSC company dedicated to advancing therapies that combat age-related degenerative diseases, including age-related macular degeneration (AMD). She achieved recognition from the California Institute for Regenerative Medicine (CIRM) for her research into stem cells during her tenure as Professor at the Buck Institute for Research on Aging.

Dr Brian Kennedy is a renowned expert in aging biology and is widely recognised for his work in translating aging research into strategies for improving longevity and preventing age-related diseases. His research focuses on the molecular mechanisms of aging and interventions that can extend healthspan, such as pharmaceuticals and lifestyle changes.

Dr Kennedy directs the Healthy Longevity Translational Research Programme at the National University of Singapore, where he is a distinguished Professor. He previously served as the President and CEO of the Buck Institute for Research on Aging, which is one of the world's leading aging research institutes.

OSX is a global medtech company that commercialises products designed to enable natural healing across multiple therapeutic areas. OSX's patented technology fabricates specific micro-structured scaffolds for tissue regeneration through 3D printing and bioresorbable material. These scaffolds are manufactured using a proprietary manufacturing technique that significantly reduces the post-surgery complications commonly associated with permanent implants.

With OSX as a strategic investor, the Regen SPV will gain access to the Company's clinical and technical advisory panel, leveraging OSX's extensive expertise in research and development, clinical trials, regulatory processes, and commercialisation to accelerate the Regen SPV's innovation and growth.

This move also solidifies the Company's leadership position in regenerative medicine.



Key Terms of the Investment Agreement:	
Total Investment	Each party (the Founders and OSX) are expected to invest in cash or in kind between USD 5 million to USD 7 million each
Osteopore Investment	Osteopore is expected to make its investments in tranches
Conditions Precedent	The proposed investment (including the level of investment by Osteopore) is subject to Osteopore being satisfied with its due diligence process, funding, and obtaining of necessary approvals

Osteopore will continue to keep the market informed of its strategic investment with the Regen SPV.

Commenting on the strategic nature of the Company's investment, Osteopore Chairman Mark Leong, said:

"Our strategic investment with Dr Zeng and Dr Kennedy places us at the forefront of regenerative medicine. The synergies created positions Osteopore as a leader in scaffold based cellular therapy unlocking numerous exciting opportunities and applications across both regeneration and rejuvenation," said Mr Leong.

Commenting on the Company's drive into cellular regeneration, Osteopore CEO Dr Yujing Lim, said:

"The clinical potential of stem cells is massive, as demonstrated by the number of clinical studies in this space. Dr Zeng and Dr Kennedy have made great strides in understanding and applying regenerative medicine and cellular therapies to repair and longevity, and we are excited to join them and contribute to this transformative journey," said Dr Lim.

Commenting on Osteopore's strategic involvement, Dr Xianmin Zeng, said:

"Osteopore's strategic investment highlights the increasing convergence of biotech and medtech. Their expertise in scaffold-based regenerative medicine and commercialisation provides us with a robust pathway to market. We are confident that, together we will accelerate development efforts and bring our life-changing therapies to fruition," said Dr Zeng.

Commenting on Osteopore's strategic involvement, Dr Brian Kennedy, said:

"This Regen SPV holds the potential of unlocking breakthroughs that make significant impacts on geroscience. By enhancing and extending functional health, it paves the way to transformative healthcare interventions," said Dr Kennedy.



The strategic investment enhances Osteopore's exposure to the USD 15.07 billion global stem cell market, which is projected to reach USD 56.15 billion by 2032 at a CAGR of 16.1% by 2032. The USA accounts for USD 8 billion of the global stem cell market - a 53.09% market share ².

This announcement dated 4 November 2024 has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Dr Yujing Lim

Chief Executive Officer

Osteopore Limited

E: lim_yujing@osteopore.com**Mel Newcombe**

Media Relations

Purple

E: mnewcombe@purple.au**About Osteopore Limited**

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

Forward-Looking Statements

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update

² <https://www.fortunebusinessinsights.com/stem-cells-market-105138>



publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement. You are cautioned not to place undue reliance on any forward-looking statement.

The forward-looking statements in this announcement reflect views held only as of the date of this announcement. This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor a tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their advice before making any investment decision.

For personal use only

